Pfizer and Valneva reported that their Lyme disease vaccine failed to meet its Phase III primary endpoint, blaming a low incidence of disease cases.

In the VALOR study (NCT05477524), which enrolled approximately 9,400 individuals over five years of age, the investigational six-valent OspA-based Lyme disease vaccine candidate PF-07307405 was 73.2% effective 28 days after the fourth dose compared to the placebo arm.

The companies said that fewer than anticipated Lyme disease cases were accrued over the study period, meaning the primary endpoint was not statistically significant. Lyme disease is a bacterial infection, primarily caused by Borrelia burgdorferi, transmitted to humans through the bite of infected blacklegged ticks.  (See link for article)

Important excerpt:

There are other vaccine candidates in earlier stages, including two messenger RNA (mRNA) vaccines, mRNA-1975 and mRNA-1982, developed by Moderna. Tonix Pharmaceuticals has also licensed a preventative monoclonal antibody (mAb), TNX-4800 which targets the outer surface protein of Borrelia burgdorferi. The drug was developed by researchers at UMass Chan Medical School.

___________

**Comment**

It’s important to point out that this ‘vaccine’ will do nothing for any coinfections, and until chronic/persistent Lyme disease is acknowledged, it’s all a mute point.  You can not vaccine for multiple pathogens and you can not vaccinate for something that is a persistent/relapsing disease.  Plus, there’s the whole sticky bioweaponization issue.

It is claimed:

The vaccine was well-tolerated, with no safety concerns. The study’s participants received four doses of the experimental vaccine or placebo in regions with high rates of Lyme.

Yet, that’s what they said about a previous Lyme vaccine called Lymerix, until previously healthy people started developing symptoms similar to tertiary syphilis and some even died.

This is all a ruse and waste of tax payer dollars.

For more: